BTAI vs CRL · rev $388.0K vs rev $2.00B
BioXcel Therapeutics Inc (BTAI) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
BTAI currently screens at market cap $36.1M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the BTAI and CRL stock pages for the full models.
Not investment advice.